论文部分内容阅读
卵巢癌预后受临床和组织病理学因素相互影响,c-erbB-2癌基因在卵巢癌发病机理中起重要作用。有报道在近25％卵巢上皮癌患者中有c-erbB-2蛋白的过度表达。本研究采用免疫组化ABC法分析106例卵巢癌石蜡包埋的肿瘤组织中c-erbB-2蛋白的过度表达。c-erbB-2表达经单抗CB11分析,将染色强度+3级定为c-erbB-2过度表达,生存时间统计采用Kaplan-Meier法。除IA和IB期病例外,其余均接受化疗:卡铂400mg/m~2iv用1天,环磷酰胺800mg/m~2iv用2天,每隔28天为一疗程,IC和Ⅱ期病例经4疗程化疗,Ⅲ和Ⅳ期病例给6疗程化疗。
The prognosis of ovarian cancer is influenced by both clinical and histopathological factors. The c-erbB-2 oncogene plays an important role in the pathogenesis of ovarian cancer. There are reports of c-erbB-2 protein overexpression in nearly 25% of patients with epithelial ovarian cancer. In this study, we used immunohistochemical ABC method to analyze the overexpression of c-erbB-2 protein in 106 cases of ovarian cancer paraffin-embedded tumor tissue. The c-erbB-2 expression was analyzed by monoclonal antibody CB11. The staining intensity of +3 grade was defined as c-erbB-2 overexpression. The survival time was calculated by Kaplan-Meier method. In addition to the IA and IB cases, the rest were treated with chemotherapy: carboplatin 400mg / m ~ 2iv with 1 day, cyclophosphamide 800mg / m ~ 2iv with 2 days, every 28 days for a course of treatment, IC and Ⅱ cases of 4 courses of chemotherapy, Ⅲ and Ⅳ cases to 6 courses of chemotherapy.